10 The antioxidant and DNA-repair enzyme apurinic/apyrimidinic endonuclease 1 limits the development of tubulointerstitial fibrosis partly by modulating the immune system

11 Prediction and Staging of Hepatic Fibrosis in Children with Hepatitis C Virus: A Machine Learning Approach.

12 Genotypic characterization of Pseudomonas aeruginosa isolates from Turkish children with cystic fibrosis

13 Peptide dendrimers as “lead compounds” for the treatment of chronic lung infections by Pseudomonas aeruginosa in cystic fibrosis patients: in vitro and in vivo studies

14 Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam

15 Impact of concomitant nontuberculous mycobacteria and Pseudomonas aeruginosa isolates in non-cystic fibrosis bronchiectasis

16 Emergence and spread of worldwide Staphylococcus aureus clones among cystic fibrosis patients

17 Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy

18 Role of small colony variants in persistence of Pseudomonas aeruginosa infections in cystic fibrosis lungs

19 Discrepancy in MALDI-TOF MS identification of uncommon Gram-negative bacteria from lower respiratory secretions in patients with cystic fibrosis

20 Genetic relatedness and host specificity of Pseudomonas aeruginosa isolates from cystic fibrosis and non-cystic fibrosis patients

21 Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis

22 Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis

23 Genotypic characterization of Pseudomonas aeruginosa isolates from Turkish children with cystic fibrosis

24 Peptide dendrimers as “lead compounds” for the treatment of chronic lung infections by Pseudomonas aeruginosa in cystic fibrosis patients: in vitro and in vivo studies

25 Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam

26 Impact of concomitant nontuberculous mycobacteria and Pseudomonas aeruginosa isolates in non-cystic fibrosis bronchiectasis

27 Emergence and spread of worldwide Staphylococcus aureus clones among cystic fibrosis patients

28 Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy

29 Role of small colony variants in persistence of Pseudomonas aeruginosa infections in cystic fibrosis lungs

30 Discrepancy in MALDI-TOF MS identification of uncommon Gram-negative bacteria from lower respiratory secretions in patients with cystic fibrosis

31 Genetic relatedness and host specificity of Pseudomonas aeruginosa isolates from cystic fibrosis and non-cystic fibrosis patients

32 Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis

33 Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis

34 Variables Associated with a Urinary MicroRNAs Excretion Profile Indicative of Renal Fibrosis in Fabry Disease Patients

35 Oral Submucous Fibrosis in Pediatric Patients: A Systematic Review and Protocol for Management

36 Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape.

37 Adipose group 1 innate lymphoid cells promote adipose tissue fibrosis and diabetes in obesity

38 Singing as an adjunct therapy for children and adults with cystic fibrosis.

39 Opportunities to Improve Utilization of Palliative Care among Adults with Cystic Fibrosis: A Systematic Review.

40 Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?

41 Antler stem cells as a novel stem cell source for reducing liver fibrosis.

42 SETTING UP OF A HOMECARE SYSTEM FOR HIGH COST NEBULISERS IN A PAEDIATRIC CYSTIC FIBROSIS CENTRE.

43 OFDM-based electrical impedance spectroscopy technique for pacemaker-induced fibrosis detection implemented in an ARM microprocessor

44 Psychological predictors of nutritional adherence in adolescents with cystic fibrosis.

45 Serum fucose level in oral cancer, leukoplakia, and oral sub mucous fibrosis: A biochemical study.

46 Loss of incretin effect contributes to postprandial hyperglycaemia in cystic fibrosis-related diabetes.

47 New insights into the immunoproteome of B. cenocepacia J2315 using serum samples from cystic fibrosis patients.

48 Congenital hepatic fibrosis and coexistent retinal macular degeneration: A case report.

49 Impact of clonally-related Burkholderia contaminans strains in two patients attending an Italian cystic fibrosis centre: a case report.

50 GH-IGF1 Axis in Children with Cystic Fibrosis.

51 Inactivation of in Abcg2 Lineage Derived Cells Drives the Appearance of Polycystic Lesions and Fibrosis in the Adult Kidney.

52 Cystic Fibrosis Transmembrane Conductance Regulator: A Possible New Target for Photodynamic Therapy Enhances Wound Healing.

53 Effect of Lumacaftor/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population.

54 Major depression and psychiatric comorbidity in Turkish children and adolescents with cystic fibrosis.

55 Thickness of the airway surface liquid layer in the lung is affected in cystic fibrosis by compromised synergistic regulation of the ENaC ion channel.

56 Specific Inhibition of the NLRP3 Inflammasome as an Anti-Inflammatory Strategy in Cystic Fibrosis.

57 Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing

58 Inspiration for the Future: The Role of Inspiratory Muscle Training in Cystic Fibrosis

59 Genetically diverse Pseudomonas aeruginosa populations display similar transcriptomic profiles in a cystic fibrosis explanted lung

60 Patient-derived pancreas-on-a-chip to model cystic fibrosis-related disorders

61 HDAC6 depletion improves cystic fibrosis mouse airway responses to bacterial challenge

62 A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis

63 A longitudinal characterization of the Non-Cystic Fibrosis Bronchiectasis airway microbiome

64 Anaerobiosis influences virulence properties of Pseudomonas aeruginosa cystic fibrosis isolates and the interaction with Staphylococcus aureus

65 Blocking RpoN reduces virulence of Pseudomonas aeruginosa isolated from cystic fibrosis patients and increases antibiotic sensitivity in a laboratory strain

66 Airway surface liquid acidification initiates host defense abnormalities in Cystic Fibrosis

67 Phenotyping ciliary dynamics and coordination in response to CFTR-modulators in Cystic Fibrosis respiratory epithelial cells

68 Longitudinal development of the airway microbiota in infants with cystic fibrosis

69 Glucose tolerance in Canadian and French cystic fibrosis adult patients

70 Changes in microbiome diversity following beta-lactam antibiotic treatment are associated with therapeutic versus subtherapeutic antibiotic exposure in cystic fibrosis

71 Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model

72 Nebulized hypertonic saline triggers nervous system-mediated active liquid secretion in cystic fibrosis swine trachea

73 Microbiome networks and change-point analysis reveal key community changes associated with cystic fibrosis pulmonary exacerbations

74 A paper-based length of stain analytical device for naked eye (readout-free) detection of cystic fibrosis

75 Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fibrosis bronchial epithelial cells

76 Furocoumarins as multi-target agents in the treatment of cystic fibrosis

77 First clinical trials of novel ENaC targeting therapy, SPX-101, in healthy volunteers and adults with cystic fibrosis

78 Liver Ultrasound Patterns in Children with Cystic Fibrosis Correlate with Noninvasive Tests of Liver Disease

79 Lactation Consultation Sustains Breast Milk Intake in Infants with Cystic Fibrosis

80 Young Patient with Cystic Fibrosis With Right Lower Quadrant Abdominal Pain

81 Prevalência de hipertensão pulmonar avaliada por ecocardiografia Doppler em uma população de pacientes adolescentes e adultos com fibrose cística Prevalence of pulmonary hypertension evaluated by Doppler echocardiography in a population of adolescent and adult patients with cystic fibrosis

82 Current dietary recommendations for patients with cystic fibrosis

83 The Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC) trial: Rationale and design of a multi-center, double-blind, placebo-controlled trial of high dose bolus administration of vitamin D3 during acute pulmonary exacerbation of cystic fibrosis

84 Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection.

85 Association between hematological profile and serum 25-hydroxyvitamin D levels and FokI polymorphism in individuals with cystic fibrosis

86 Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia.

87 Smooth Muscle α-actin Deficiency Leads to Decreased Liver Fibrosis via Impaired Cytoskeletal Signaling in Hepatic Stellate Cells.

88 siRNA- and miRNA-based therapeutics for liver fibrosis.

89 Liver fibrosis staging with combination of APRI and FIB-4 scoring systems in chronic hepatitis C as an alternative to transient elastography.

90 Parathyroid hormone-related protein activates HSCs via hedgehog signalling during liver fibrosis development

91 Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease

92 Reversal of established liver fibrosis by IC-2-engineered mesenchymal stem cell sheets

93 Adoptive Transfer of Bone Marrow-Derived Monocytes Ameliorates Schistosoma mansoni -Induced Liver Fibrosis in Mice

94 A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms

95 Development and validation of a primate model for liver fibrosis

96 Chronic exposure to tetrabromodiphenyl ether (BDE-47) aggravates hepatic steatosis and liver fibrosis in diet-induced obese mice

97 Docosahexaenoic acid inhibits hepatic stellate cell activation to attenuate liver fibrosis in a PPARγ-dependent manner

98 Wogonin attenuates liver fibrosis via regulating hepatic stellate cell activation and apoptosis

99 Characteristics of liver fibrosis associated with chronic Opisthorchis felineus infection in Syrian hamsters and humans

100 Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease

101 A liver fibrosis staging method using cross-contrast network

Keyword Connections

Journals

Research Groups

Bibliographies